- Details
- Maria De Santis discusses managing frail patients with metastatic hormone-sensitive prostate cancer. Dr. De Santis explains the importance of defining frailty, which involves five key factors: unintended weight loss, weakness, low physical activity, difficulty lifting objects, and mobility issues. She highlights the necessity of evaluating frailty using tools like the G8 screening and emphasizes t...
|
- Details
- Michael Morris discusses optimal imaging standards for metastatic hormone-sensitive prostate cancer. He explains that conventional imaging methods like PSA tracking are insufficient for monitoring disease progression in the era of advanced androgen receptor signaling inhibitors (ARSIs). Dr. Morris emphasizes the need for regular imaging, recommending scans every six to twelve months to detect radi...
|
- Details
- Zach Klaassen discusses the EvoPAR-Prostate 01 trial with Neeraj Agarwal. The trial examines a new PARP inhibitor combined with ARPI in metastatic hormone-sensitive prostate cancer, both in biomarker-positive and -negative populations. Dr. Agarwal explains the rationale based on preclinical data and previous trials like PROpel and TALAPRO-2, showing efficacy in HRR mutation-positive patients and p...
|
- Details
- Alicia Morgans speaks with Bertrand Tombal about his presentation at EAU 2024, focusing on the European subset of the ARASENS trial. Professor Tombal discusses the importance of the data from this trial, which assessed the efficacy of adding darolutamide to standard treatment for metastatic hormone-naive prostate cancer. The trial confirmed that this combination significantly reduced mortality ris...
|
- Details
- Alicia Morgans and Alberto Bossi discuss the integration of local prostate treatment in metastatic hormone-sensitive prostate cancer, focusing on findings from the PEACE-1 trial and related studies. Professor Bossi highlights the challenge in identifying patients who could benefit most from local radiotherapy, especially given the evolution in imaging technologies like PSMA PET, which may redefine...
|
- Details
- Zach Klaassen and Kelvin Moses discuss the continuum of care for metastatic hormone-sensitive prostate cancer, focusing on triplet therapy. Dr. Moses highlights the ideal patient profile for this treatment, emphasizing collaboration between urology and medical oncology. They stress the manageable nature of chemotherapy and its finite duration. The conversation extends to disparities in prostate ca...
|
- Details
- Alicia Morgans engages in a discussion with Benjamin Lowentritt, focusing on comprehensive care for prostate cancer patients, particularly those with de novo metastatic hormone-sensitive disease. Dr. Lowentritt shares a patient case illustrating the challenges and strategies in managing such cases over time. They emphasize the importance of multidisciplinary teams and seamless communication betwee...
|
- Details
- Alicia Morgans hosts a discussion with Paul Eber and Brad Somer to explore the collaborative management of metastatic hormone-sensitive prostate cancer cases. They highlight a unique partnership between urology and medical oncology in Memphis, Tennessee, emphasizing the importance of teamwork in treating patients, especially in underserved areas. Dr. Eber shares his experience with patients presen...
|
- Details
- Christopher Pieczonka discusses the management of metastatic hormone-sensitive prostate cancer with a focus on triple therapy. Dr. Pieczonka emphasizes that androgen deprivation therapy (ADT) is no longer the standard of care as monotherapy for metastatic prostate cancer, citing the ARASENS study's results, which demonstrate the overall survival benefit of adding docetaxel and Nubeqa to ADT. He su...
|
- Details
- Alicia Morgans discusses the evolving strategies for treating metastatic hormone-sensitive prostate cancer (mHSPC) with Karim Fizazi. Professor Fizazi critiques the traditional method of classifying metastatic disease by the volume of metastases, advocating for a more nuanced approach. He highlights recent phase three trials that suggest a shift away from simply categorizing disease into low and h...
|
